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Precision medicine in the clouds 
 
To the editor: 
 
A billion-dollar question is whether precision medicine (aka personalized, “P4” or systems 
medicine) can substantially increase the utility of individualized disease prevention and 
population health1,2. In this respect, the first results from the “Pioneer 100 Wellness Project 
(P100)” featured in last August’s Nature Biotechnology issue, is a landmark3,4. The study sheds 
light on an approach that has primarily existed as a vision and precedes the US National 
Institutes of Health’s (NIH; Bethesda, MD) “All of Us Study”, which will include a million 
participants in a similar scheme (http://www.allofus.nih.gov/). The researchers behind the study 
claim to demonstrate how measurement of personal data clouds over time can improve our 
understanding of health and disease and to identify “actionable possibilities”, by which 
individuals can enhance health through preventive strategies. 
P100 is an exploratory study of associations in networks of biomarkers and risk factors 
established from large and dynamic data clouds of 108 participants. Over the course of a 9-
month period, participants underwent whole genome sequencing (yielding 127 polygenic scores 
for disease risks plus three copy number variations), three-times testing of metabolome (643 
metabolites), proteome (262 proteins) and microbiome (4616 taxonomic units), 218 other clinical 
tests and measurements, as well as daily activity tracking via “quantified self” technologies. 
Associations between these biomarkers yielded a total of 3470 connections in a correlation 
network. The P100 study is a project designed to display the potentials for novel technologies 
and gather support for precision or P4 medicine (predictive, preventive, personalized and 
participatory), and it has gained prominent publicity in Nature5. The P100 will also be scaled up 
to include 100,000 participants in the 100K Wellness Project3. Against this background, we here 
discuss whether the P100 study actually supports the prospect of substantial benefits from data-
driven disease prevention, and argue that it exposes severe challenges. 
The graphics of the correlational networks presented by Price et al.3 do offer an 
interesting research potential for exploring connections in molecular networks and for 
identifying candidate biomarkers3. However, as yet there are only a few examples where such 
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approaches have led to novel discoveries of therapeutic potential, especially when it comes to 
disease prevention which is the main aim of P100. Systems medicine has very ambitiously been 
promoted as a “holistic” approach that will “tackle all components of the complexity of non-
communicable diseases”6. It is, of course, not obvious that scientific models can ever encompass 
all factors that will determine an individual´s health. The P100 also illustrates that the 
purportedly "holistic" ambition of quantitative systems medicine is far from being realized as it 
employs a reductionist method defined less by true integration than collection and correlation of 
diverse, but mostly molecular, data. 
In terms of clinical research method, the P100 does not involve a classic randomized trial 
with a control group (RCT). Instead its leading researchers opt for an ambitious, but ill-defined 
n-of-1 approach where each participant is extensively monitored and considered his/her own 
control. Quote Leroy Hood: “We hope to develop a whole series of stories about how actionable 
opportunities have changed the wellness of individuals”5. In line with this reasoning, the authors 
present changes in clinical biomarkers during the 9-month study as evidence for clinical utility. 
However, to measure an unbiased, valid effect in an n-of-1 randomized clinical trial, the study 
would have to include pairs of organized periods so that one period of each pair applies the 
experimental therapy and the other period applies usual care or placebo, and both the clinician 
and the patient have to be blinded7. In the P100 study, these strict methodological criteria do not 
apply. For example, this makes it difficult to examine whether people alter their behavior in 
response to just being observed (the Hawthorne effect). Proponents of preventive precision 
medicine may argue that there are other ways of providing evidence for treatment efficacy as the 
number of measured variables increases and the number of research subjects that are similar 
enough for a personalized approach, moves towards n=1. This may involve continuous 
monitoring to observe significant changes in each particular person. The prospect of using such 
big data “narratives” as evidence is intriguing. However, the P100 study fruitfully highlights how 
important epistemological and methodological questions must be clarified and answered before it 
is clear how it is determined who is at risk and what treatments actually work.  
 
In general, it is not clear what the key concepts of “actionability” or “clinical utility” refer 
to in the P100 study. We do not know how much action the participants were actually able to 
take when faced with “actionable possibilities”, or how useful it was for them. The competence 
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of the health coaches and the rationale for their “personalized” health recommendations are 
unknown, although the latter are described as being “evidence-based” and mostly consist of 
advice on diet, exercise, stress management, dietary supplements, or physician referral.  
Importantly, the effects are measured mostly in terms of correction of surrogate 
endpoints. As a general point, such changes provide no guarantee for changes neither in the hard 
endpoints of morbidity and mortality, nor in quality of life. As an example, a study carrying out a 
10-year follow-up on the large, five-year Inter99-study8, which tested lifestyle counselling based 
on screening for risk factors, showed no significant difference between the intervention and 
control groups with respect to ischemic heart disease, stroke, or mortality, despite successful 
changes in risk factors as in the P100 study9. 
In P100, changes in vitamin D levels and markers for pre-diabetes are interpreted as 
evidence of health benefits. 88% of the participants were labeled as out of range at baseline in 
their vitamin D levels. Although the participants “out of range” managed to increase their 
vitamin D levels with 7.2 ng/mL per round, it is questionable whether vitamin D supplements 
change hard endpoints10.  
As another staggering figure, 48% of the previously well individuals were deemed to 
have “out of-range” HbA1c levels (glycated hemoglobin) and were labeled as pre-diabetic. 
Again, what these participants would gain from lowering HbA1c by 0.085% per round is 
unclear. A third example is mercury levels. It is blatantly unclear how valid and useful it is to 
label 81 out of 108 participants with a mercury problem that on average was lowered by 0.002 
mcg/g/round. 
More generally, vitamin D deficiency and pre-diabetes are examples of controversies in 
preventive medicine, both being criticized for questionable clinical utility, connections to 
alternative medicine, overmedicalization and unsustainable burdens on the healthcare system11,12. 
One case story is given special attention as evidence of potential benefit in the P100 
publication3. A 65-year-old male presented symptoms to his physician and was found to have 
abnormally high ferritin levels. Genetic testing showed that he was homozygous for the primary 
genetic risk factor for hemochromatosis. In a commentary4, Butte claims that this particular 
example teaches us that “genomes can provide useful medical information to healthy 
individuals”. However, testing after experience of symptoms is a very different matter from 
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screening asymptomatic people, which is what the P100 is otherwise about. It is not clear that the 
man had fared any worse with regular primary care. It should also be noted that generalized 
screening of asymptomatic individuals for hereditary hemochromatosis is yet another 
controversial case in preventive medicine13. 
Another important question is whether precision medicine can actually “empower” 
people to change their lifestyles in response to risk information. Although there are studies 
showing some positive results, a general trend in available evidence is that lifestyle interventions 
and health checks among the apparently healthy are of limited benefit 8,9,14–16.. One common and 
difficult challenge is that people simply often do not follow recommendations. Proponents of 
prevention precision medicine may argue that a personalized approach is needed precisely to 
provide the individual with more accurate risk assessments and advice so that they may change 
their behaviors according to their particular case. However, a recent systematic review with 
meta-analysis has showed that there is no clear evidence for a significant positive impact of 
communicating individualized genetic risks of disease on risk-reducing health behaviour15.  
P4 medicine now promises to change this picture through continual, multi-level feedback 
on personal health. However, the P100 illustrates that the approach may be up against quite 
fundamental challenges: Only 64% of the participants complied with Fitbit activity tracking for 
40 days out of 9 months (and even fewer for sleep tracking)—a striking result considering that 
the participants (largely middle-class volunteers) were presumably unusually motivated. The 
prospect of significant benefits from the preventive precision medicine should also be considered 
in light of increasing evidence that risk information and extensive self-tracking generally have 
little effect on health-related actions17-18.  
This is not to say that counselling or coaching based on risk estimates and screening does 
not has an effect for some people, as several studies show9. However, taken together, such results 
call for modesty concerning the prospects of extensive self-monitoring to improve population 
health greatly, especially in providing strategies that benefit those who live their lives in health-
detrimental environmental situations, who are at high risk and in the greatest need of medical 
care19 As the authors of the abovementioned Inter99 study state, the implication of the generally 
weak results of screening and lifestyle counselling is that health behavior depends on the 
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individual´s social context and life conditions and that interventions should therefore be mostly 
be structural rather than targeted at individuals9. 
Although extensive measurement and testing may have some benefits, these must be 
weighed against harms and costs. The P100study seems solely geared towards showing benefits, 
we must consider possible downsides of this approach on a theoretical basis.  
The most important finding in the P100 study may be that all of the 108 participants were 
found to have multiple “actionable possibilities” and thus were labeled as in need of medical 
attention. To define everyone as at risk is clearly not very precise. It is also potentially harmful. 
To underscore, these people considered themselves well at baseline, but upon entering the study, 
they were all regarded as in suboptimal health. This entails a change in identity, and may result 
in pathologization and worry20,21.  
Crucially, the P100 highlights the problem of overdiagnosis (i.e., discovery of real but 
asymptomatic abnormalities that will never become symptomatic health problems). 
Overdiagnosis is a serious problem because it often leads to costs and harms associated with 
overtreatment and further over-testing, while it cannot, by definition, benefit those who would 
never develop symptomatic disease. 
Recent meta-analyses show that the problem of overdiagnosis is not only due to a lack of 
predictive power in medical testing, but to medical overactivity more generally. The problem 
increases with lowered diagnostic thresholds, intensified screening for early disease and risk 
states, diagnostic technologies with higher resolution, and through more frequent and intensified 
measurements of multiple parameters22. The P100 approach includes all of these potential 
“drivers of overdiagnosis”. Previously published papers commenting on the P100 study have 
raised concerns about the increased risk of overdiagnosis1,23,24. The P100 researchers 
acknowledge false-positive tests, but have not addressed overdiagnosis, neither in previous 
papers nor in the current publication3,25.  
We should also consider opportunity costs: The P100 strategy means a large investment 
for each participant (and society), both in terms of money, time and attention. What could have 
been gained in terms of health and other benefits had the resources been used otherwise?  
What have we learned from the P100 study? This question is difficult to answer. The 
study does not follow available guidelines for assessment of public health impact of medical 
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testing. This is particularly disconcerting as the project is the pilot for the much larger 100K 
Wellness Project. P100 promotes a novel concept that is branded as “scientific wellness”. 
However, in practice the study represents a form of data-driven screening for early disease and 
risk states that entails an unprecedented over-medicalization in terms of measurements and 
interventions24. The benefit the previously well participants reap from this is literally in the 
(data) clouds. 
The P100 study highlights the need to discuss how high a price we are willing to pay to 
explore the potential of P4 medicine, and whether we currently have unrealistic expectations to 
the new technologies. Overstating the potential may influence personal and political choices, and 
divert attention and resources from strategies that may be more effective. Researchers who 
develop technologies for preventive medicine should take its profound challenges seriously—
especially overdiagnosis. To make informed choices about the future of healthcare, we need 
studies that substantiate what we may call “actionable evidence”, i.e., studies showing changes in 
hard endpoints that take seriously the risk of unintentional harm. In the context P4 medicine or 
precision medicine, the balance between promises and evidence should be better calibrated. 
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